Los puntos clave no están disponibles para este artículo en este momento.
Humoral immune sensitization occurs during treatment with chemotherapy and trastuzumab. Further studies are warranted to investigate whether augmented anti-HER-2/neu humoral and cellular immunity contributes mechanistically to clinical outcome.
Taylor et al. (Sat,) studied this question.